Health Catalyst, Inc. (HCAT) Stock Forecast
HCAT analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.40 / 5 from 5 analysts
- Price target
- $1.77 average of analyst targets
- Upside to target
- +2.4% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.07
- 52-week range
- $1.00 – $3.46
HCAT analyst ratings
5 analystsNumber of analysts at each rating.
HCAT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HCAT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.07 | −$0.02 | $0.06 | −179.2% | 4 |
| Current fiscal year (2026) | −$0.04 | −$0.07 | $0.00 | $0.18 | −119.4% | 4 |
| Next fiscal year (2027) | $0.01 | −$0.12 | $0.10 | −$0.04 | +121.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HCAT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $55.4M | $55.1M | $55.9M | −27.4% | 5 |
| Current fiscal year (2026) | $247.8M | $246.3M | $250.5M | −20.3% | 5 |
| Next fiscal year (2027) | $205.5M | $192.5M | $221.1M | −17.1% | 5 |
HCAT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HCAT revenue: reported and forecast
HCAT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.00 | −$0.00 | −$0.05 | −$0.05 | −$0.05 | +11,775.0% | 0 up · 3 down |
| Current fiscal year (2026) | $0.04 | $0.04 | −$0.05 | −$0.05 | −$0.04 | −183.3% | 0 up · 4 down |
| Next fiscal year (2027) | $0.09 | $0.09 | $0.01 | $0.01 | $0.01 | −91.9% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HCAT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HCAT beat in 6 of 12.
What analysts expect from HCAT
5 analysts cover Health Catalyst; their consensus rating is hold (3.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.77, 2.4% above the latest close of $1.73. Analysts expect earnings of −$0.04 per share for 2026, −119.4% from a year earlier. For 2027 the average estimate is $0.01 per share on revenue of $205.5 million. Health Catalyst beat the EPS estimate in 6 of the last 12 quarters.
Related: HCAT income statement, HCAT key metrics, HCAT chart. See the HCAT stock overview for the latest quote and news.
HCAT forecast FAQ
What is Health Catalyst's price target?
The average analyst price target for Health Catalyst is $1.77, 2.4% above the latest close of $1.73.
Is Health Catalyst a buy, hold or sell?
Of 5 analysts covering Health Catalyst, 1 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Health Catalyst's EPS forecast?
Analysts forecast −$0.04 per share for 2026 (range −$0.07 to $0.00); for 2027 the estimate is $0.01.
What is Health Catalyst's revenue forecast?
The average revenue estimate for 2026 is $247.8 million, growth of −20.3%; for 2027 it is $205.5 million.
When does Health Catalyst report earnings?
Health Catalyst is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.07.
Does Health Catalyst usually beat earnings estimates?
Health Catalyst reported EPS at or above the analyst estimate in 6 of the last 12 quarters.